Eminent clinical leaders in oncology, mesothelioma, CAR-T cell therapies, haematology and immunology and have been assembled to guide development of BZDS1901, our ground breaking armoured CAR-T cell therapy for mesothelioma and other solid cancers.

AdAlta’s Consultant Chief Medical Officer, Dr Kevin Lynch said:

“Together these eminent clinicians provide leadership and deep expertise in clinical oncology, mesothelioma, solid cancer CAR-T cell therapies, haematology and immunology, disciplines that are all necessary to safely and efficiently deliver BZDS1901 to patients with solid tumours. We are delighted that they have agreed to help us guide the further development of BZDS1901 and to ensure that Australian patients with mesothelioma and other mesothelin-expressing tumors are the first to have access to this potentially ground-breaking therapy outside China.”